Abstract:An increasing number of artemisinin (ARS) and its derivatives have been reported for their potential therapeutic value of human cancer. However, their therapeutic potencies are limited owing to their poor pharmacokinetic profiles. Our previous studies showed that a lead compound ARS4 originated from incorporating the pharmacophore of the approved chemotherapeutic agent melphalan into the basic skeleton of artemisinin with a succinic linker exhibited an excellent toxicity to human ovarian cancer cells and low cytotoxicity to normal cells. The mechanism studies demonstrated that it inhibited the growth and proliferation of ovarian cancer cells and resulted in S-phase arrest, apoptosis and inhibition of migration. Meanwhile, it exhibited excellent antitumor activities in animal models. Herein, further structure optimization for this lead compound ARS4 was performed and nineteen novel derivatives were designed and synthesized. Among them, compounds 10-12, 15, 16, 18 and 19 demonstrated powerful cytotoxic effects against human liver cancer and ovarian cancer cell lines, with their IC50s below 0.86 μM against Hep3B and A2780 cell lines, which are superior to that of ARS4. Four compounds (11, 15, 16 and 18) were selected to further evaluate their antitumor activities in in vitro and in vivo ovarian and liver cancer models, the results indicated that compound 18 exhibited the best therapeutic effect, not only effectively inhibited the growth of 7404 xenograft and Huh7 xenograft, but also presented a good dose-dependent inhibition toward the growth of A2780 xenograft. Overall, based on these positive results, these novel chemical structures may provide a new inspiration for the discovery of novel antitumor agents originated from artemisinin scaffolds.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new artemisinin derivatives in order to improve their therapeutic effects on liver cancer and ovarian cancer. Specifically, researchers hope to design and synthesize new artemisinin derivatives through structural optimization. These derivatives can overcome the pharmacokinetic deficiencies of existing artemisinin and its derivatives, such as poor metabolic stability and low bioavailability, thereby enhancing their anti - tumor activities. ### Background Artemisinin (ARS) and its derivatives have been widely used in anti - malaria treatment and have shown potential anti - cancer activities. However, due to their poor pharmacokinetic properties (such as low metabolic stability and bioavailability), their therapeutic effects are limited. To overcome these shortcomings, researchers have carried out a great deal of structural optimization work, aiming to discover new artemisinin derivatives with higher biological activities. ### Research Objectives 1. **Structural Optimization**: Design and synthesize new artemisinin derivatives by introducing different linking groups and substituents. 2. **Biological Evaluation**: Evaluate the cytotoxicity and anti - tumor activities of these new derivatives against liver cancer and ovarian cancer cell lines. 3. **Mechanism Research**: Explore the anti - tumor mechanisms of these derivatives, including cell cycle arrest, apoptosis induction, and migration inhibition. ### Main Findings - **Design and Synthesis of New Derivatives**: Researchers designed and synthesized 19 new artemisinin derivatives. - **Cytotoxicity Evaluation**: Among them, compounds 10 - 12, 15, 16, 18, and 19 showed strong cytotoxicity, with IC50 values lower than 0.86 μM against liver cancer and ovarian cancer cell lines, which were better than the lead compound ARS4. - **In Vivo Experiments**: The anti - tumor activities of four compounds (11, 15, 16, and 18) were further evaluated in in - vivo models. The results showed that compound 18 exhibited the best therapeutic effect in liver cancer and ovarian cancer xenograft models. ### Conclusion Through structural optimization, researchers have successfully designed and synthesized a variety of new artemisinin derivatives. These derivatives have shown excellent anti - tumor activities in both in - vitro and in - vivo experiments. In particular, compound 18 not only showed strong cytotoxicity in in - vitro experiments but also showed significant therapeutic effects in in - vivo experiments. Although there are some side effects (such as weight loss), these results provide important implications for the development of new anti - tumor drugs. Future research will further optimize the structures of these derivatives to overcome existing deficiencies.

Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents

Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis.

Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties

Novel artemisinin derivatives with potent anticancer activities and the anti-colorectal cancer effect by the mitochondria-mediated pathway

Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

Artematrovirenolides A—D and Artematrolides S—Z, Sesquiterpenoid Dimers with Cytotoxicity against Three Hepatoma Cell Lines from Artemisia atrovirens

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Artemisinin and Its Derivatives as Potential Anticancer Agents

Development and evaluation of novel artemisinin-isatin hybrids with potential anti-leukemic cytotoxicity

Synthesis and Cytotoxic Activities of Novel Ether Conjugates of Dihydroartemisinin and Zerumbone: Evidenced by Intergrating Network Pharmacology and In Vitro Assay

Synthesis of N-11-Anchoring Biotinylated Artemisinin Derivatives and Their Preliminary Biological Assessment

Discovery of novel dihydroartemisinin-cinnamic hybrids inducing lung cancer cells apoptosis via inhibition of Akt/Bad signal pathway

Discovery of Platinum IV -Artesunate Multiaction Prodrugs as Potent Antitumor and Antimalarial Agents

Synthesis, crystal structure, DFT and anticancer study of dihydroartermisinin-paracetamol hybrids

Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities